Valeant’s New CFO Will Review 2016 Numbers, CEO Papa Says

  • Asset sales will be announced in next six months, Papa says
  • Some divested assets may go for less than Valeant paid

Valeant Pharmaceuticals International Inc.’s new chief financial officer will review the drugmaker’s numbers for this year and next after the company surprised the market in August by reaffirming its 2016 forecast, Chief Executive Officer Joe Papa said in an interview Tuesday.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.